A double-blind placebo-controlled randomized phase II trial assessing the activity and safety of regorafenib in non-adipocytic sarcoma patients previously treated with both chemotherapy and pazopanib - Archive ouverte HAL Access content directly
Journal Articles European Journal of Cancer Year : 2020

A double-blind placebo-controlled randomized phase II trial assessing the activity and safety of regorafenib in non-adipocytic sarcoma patients previously treated with both chemotherapy and pazopanib

(1) , (2) , (3) , (4) , (5) , (6) , (7) , (8) , (9) , (10) , (11) , (12) , (13) , (14) , (15) , (16) , , (15) , (15, 17) , (4)
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
Nicolas Penel
Olivier Mir
Isabelle Ray-Coquard
Antoine Italiano
Lucie Laroche
  • Function : Author
Jean-Yves Blay
Not file

Dates and versions

hal-03623680 , version 1 (29-03-2022)

Identifiers

Cite

Nicolas Penel, Olivier Mir, Jennifer Wallet, Isabelle Ray-Coquard, Axel Le Cesne, et al.. A double-blind placebo-controlled randomized phase II trial assessing the activity and safety of regorafenib in non-adipocytic sarcoma patients previously treated with both chemotherapy and pazopanib. European Journal of Cancer, 2020, 126, pp.45-55. ⟨10.1016/j.ejca.2019.12.001⟩. ⟨hal-03623680⟩
22 View
0 Download

Altmetric

Share

Gmail Facebook Twitter LinkedIn More